SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna
IgG apheresis
SARS-CoV-2 IgG spike (S) protein antibody
covid-19
immunoadsorption
vaccination
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
06
2022
accepted:
30
08
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
The SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG) apheresis to control autoimmune disease activity is unknown. We aimed to examine the humoral immune response after mRNA-1273 Moderna We prospectively monitored SARS-CoV-2 IgG spike (S) protein antibody levels before and after each IgG ( We included 6 IgG and 18 LDL apheresis patients. After 12 weeks the median SARS-CoV-2 IgG S antibody level was 115 (IQR: 0.74, 258) in the IgG and 1216 (IQR: 788, 2178) in the LDL group (p=0.03). Median SARS-CoV-2 IgG S antibody reduction by apheresis was 76.4 IgG apheresis patients had lower SARS-CoV-2 IgG S antibody levels compared to LDL apheresis patients, but recovered appropriately between treatment sessions. We believe that IgG apheresis itself probably has less effect on maintaining the immune response compared to concomitant immunosuppressive drugs. Immunization is recommended independent of apheresis treatment.
Sections du résumé
Background
The SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG) apheresis to control autoimmune disease activity is unknown. We aimed to examine the humoral immune response after mRNA-1273 Moderna
Methods
We prospectively monitored SARS-CoV-2 IgG spike (S) protein antibody levels before and after each IgG (
Results
We included 6 IgG and 18 LDL apheresis patients. After 12 weeks the median SARS-CoV-2 IgG S antibody level was 115 (IQR: 0.74, 258) in the IgG and 1216 (IQR: 788, 2178) in the LDL group (p=0.03). Median SARS-CoV-2 IgG S antibody reduction by apheresis was 76.4
Conclusions
IgG apheresis patients had lower SARS-CoV-2 IgG S antibody levels compared to LDL apheresis patients, but recovered appropriately between treatment sessions. We believe that IgG apheresis itself probably has less effect on maintaining the immune response compared to concomitant immunosuppressive drugs. Immunization is recommended independent of apheresis treatment.
Identifiants
pubmed: 36225921
doi: 10.3389/fimmu.2022.969193
pmc: PMC9549982
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Lipids
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
969193Informations de copyright
Copyright © 2022 Gaggl, Aschauer, Aigner, Bond, Vychytil, Strassl, Wagner, Sunder-Plassmann and Schmidt.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Rheumatology (Oxford). 2022 Jul 6;61(7):2815-2825
pubmed: 34792562
Clin Microbiol Infect. 2016 Jul;22(7):589-93
pubmed: 27093875
J Neurol. 2022 Aug;269(8):4000-4012
pubmed: 35503375
RMD Open. 2022 Feb;8(1):
pubmed: 35115385
JAMA Intern Med. 2022 Feb 1;182(2):165-171
pubmed: 34928302
Ther Apher Dial. 2003 Feb;7(1):91-7
pubmed: 12921122
J Heart Lung Transplant. 2022 Jun;41(6):765-772
pubmed: 35606065
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Ther Apher Dial. 2022 Feb;26(1):229-241
pubmed: 33914397
Transplantation. 2022 Oct 1;106(10):1940-1951
pubmed: 35509090
Lancet Reg Health Eur. 2021 Oct;9:100178
pubmed: 34318288
J Infect Dis. 2018 Sep 8;218(8):1191-1199
pubmed: 30007341
Transplantation. 2022 Apr 1;106(4):821-834
pubmed: 34753894
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
Atheroscler Suppl. 2017 Nov;30:217-224
pubmed: 29096841
Atheroscler Suppl. 2009 Dec 29;10(5):89-94
pubmed: 20129383
Ann Rheum Dis. 2021 Oct;80(10):1322-1329
pubmed: 34362747
J Am Soc Nephrol. 2021 Sep;32(9):2147-2152
pubmed: 34112706
Curr Transplant Rep. 2022;9(3):174-184
pubmed: 35506151
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Ann Lab Med. 2015 Sep;35(5):506-9
pubmed: 26206687
Nephrol Dial Transplant. 2021 Mar 09;:
pubmed: 33693778
Infection. 2021 Jun;49(3):501-509
pubmed: 33537915
Vaccines (Basel). 2021 Oct 12;9(10):
pubmed: 34696273
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Atheroscler Suppl. 2009 Dec 29;10(5):114-21
pubmed: 20129388
Kidney Int. 2021 Jun;99(6):1498-1500
pubmed: 33887315
JCI Insight. 2022 May 9;7(9):
pubmed: 35349490